Novozymes Biopharma and Upperton Limited Granted European Patent for Oncology Technology
The newly-granted patent describes methods of conjugating antibodies and other targeting agents to protein carriers by means of a heterobifunctional linker. In doing so, it is possible to deliver large quantities of drugs and other agents to selected sites in the body.
The initial focus for the technology will be in oncology. One such application involves using monoclonal antibodies to target recombinant albumin loaded with, for example, a chemotherapeutic agent to cancer cells. By using the carrier properties of albumin, it is possible to target significant quantities of chemotherapeutic agents or radioactive metal ions to cancer cells, whilst retaining the sensitive binding property of the targeting antibody. The result is a significant increase in the amount of therapeutic agent that can be delivered to its target compared to standard administration methods.
Upperton is now in the process of seeking development partners to exploit its drug delivery platform. It is anticipated that the Upperton technology platform will add value across a wide a range of pharmaceutical applications. The current focus is in oncology but other areas that are growing in interest include the delivery of nucleic acids for the rapidly growing siRNA market.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous